Policymakers recently have focused on the 340B program as its size increased. Whole cottage industries have been created that instruct how hospitals and contract pharmacies can profit from the loose regulations, to the point that the drug industry can no longer overlook the market inefficiencies Yet despite several oversight hearings by the House Energy & Commerce Committee, Congress could not come to a consensus on how to reform it.
Many analysts believe the Republican base’s frustration with the inability of the party to repeal Obamacare makes a Democrat takeover of Congress in 2018 a real possibility. An examination of Democratic health priorities is therefore in order.
Frustrated with congressional Republican inaction on major pieces of his agenda, President Trump cut deals with Democrats on a short-term increase in the debt ceiling and funding the government. Then to the surprise and consternation of his base, Trump agreed to work on a deal to extend DACA, a Democratic priority. But what does Trump’s new interest in working with Democrats mean for healthcare policy-making? That is not yet clear.
Lost in the hubbub over drug pricing has been the flat and declining spending recently in Part D. The Congressional Budget Office’s (CBO) June 2017 Baseline projections show that Part D spending stabilized at $95 billion annually for 2016 and 2017 and will decline to $92 billion in 2018.
This month, our Washington D.C. insider discusses the 340B drug discount program and the 340B Hospital Outpatient proposed rule. “Notwithstanding the hoopla over the CMS proposal, a proposed rule does not necessarily mean it will become finalized policy.”
After the House of Representatives passed The American Health Care Act — the bill that would replace Obamacare — by a razor-thin margin, consideration moved to the Senate, where Republicans have only two votes to spare to secure passage.
At a Stanford University conference last week, Office of Management and Budget (OMB) Director Mick Mulvaney said President Trump keeps asking him what he is doing to address the high cost of pharmaceuticals.
As Republicans attempt to recover from their face-plant on repealing and replacing Obamacare, policymakers are grappling with how to address the growing problem of healthcare provider consolidation, which appears to be raising costs and undermining competition.
To understand the political peril Republicans confront in their effort to repeal and replace Obamacare, it is worth noting that many of the areas that gained the most coverage from Obamacare are the working-class districts carried by President Trump with the largest margins.
After bracing for the worst, pharmaceutical executives emerged from a White House meeting with newly installed President Donald J. Trump relatively unscathed. But they soon concluded that his ever-roving spotlight would be back on them in a matter of time.
Our new President seemed to criticize recent inversions, but more importantly vowed to go after the industry: “Our drug industry has been disastrous.
The Republican sweep in the 2016 elections hands the enormous power of the Center for Medicare and Medicaid Innovation (CMMI) to the Trump administration. What to do with this power?
The stunning Trump victory and the Republican hold in the Senate, giving the GOP full control over the executive and legislative branches, provides some breathing space for a pharmaceutical industry that increasingly felt under siege.
As the most bizarre and unpredictable election season draws to a close, scrutiny is turning to wikileaked emails among senior officials in the Clinton campaign licking their chops to take on the pharmaceutical industry, and healthcare policymaking by the executive branch.
Six years after the enactment of the Affordable Care Act (ACA), policymakers are just beginning to appreciate a little-known provision that essentially outsources Congress’ authority over Medicare to the executive branch.
Three top biopharmaceutical executives share their ideas on what bio clusters biopharmaceutical executives should be paying attention to for 2018. In addition, insights are provided on other future potential bio hot spots.
Five top biopharmaceutical executives share their thoughts on Big Data, industry trends, personalized medicine, and more in preparing you for what to expect in 2018 – and beyond.
Five female biopharmaceutical industry CEOs share exclusive insights on what to expect for 2018 and beyond.
A behind the scenes look into the educational planning for the 2018 BIO International Convention in Boston.
In the December 2017 issue’s article, “The Women of Biopharma — Will They Gain or Lose Ground in 2018?” we summarize the responses of those who chose to contribute as panelists in a “virtual roundtable” discussion. Here, as promised, we are posting their written responses in full.